Novo Nordisk CEO retains faith in obesity business
![Photo: Stine Bidstrup/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14282414.ece/ALTERNATES/schema-16_9/doc7m5phr9iy2u6rx0fvh.jpg)
Although investors have punished Novo Nordisk on the stock exchange in an apparent reaction to a couple of obesity-related disappointments, there is still faith in the growth predictions for the obesity market at the firm.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.